logo-loader
MaxCyte

MaxCyte raises £10mln to extend its CARMA platform into a second trial

MaxCyte Inc (LON:MXCT) CEO Doug Doerfler sits down with Proactive at the BIO CEO and Investor Conference in New York.

The company has raised £10mln in a share placing to fund an acceleration of its growth strategy as well as executing “significant commercial opportunities”.

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read